Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use

[1]  F. Erdoğan,et al.  Prognostic significance of morphologic parameters in renal cell carcinoma , 2004, International journal of clinical practice.

[2]  Kayo Nakamura,et al.  Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. , 2002, Immunity.

[3]  M. Fishman,et al.  Immunotherapy of metastatic renal cell cancer. , 2002, Cancer control : journal of the Moffitt Cancer Center.

[4]  F. Marincola,et al.  A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma , 2002, Journal of immunotherapy.

[5]  A. Enk,et al.  Dendritic cells as a tool to induce anergic and regulatory T cells. , 2001, Trends in immunology.

[6]  J. Blay,et al.  IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. , 2001, Cancer research.

[7]  S. Riddell,et al.  Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells , 2001, Nature Immunology.

[8]  Nicholas R. English,et al.  Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.

[9]  N. Rioux-Leclercq,et al.  Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer. , 2000, European Cytokine Network.

[10]  T. Whiteside,et al.  Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. , 2000, Cancer research.

[11]  A. Gross,et al.  Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids , 2000, Nature Medicine.

[12]  R. Figlin,et al.  Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M Mazumdar,et al.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  T. Cloughesy,et al.  Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. , 1999, Journal of neurosurgery.

[15]  M. Roth,et al.  Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  A. Ravaud,et al.  Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .

[17]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[18]  L. Sobin,et al.  TNM staging of renal cell carcinoma , 1997, Cancer.

[19]  R. Figlin,et al.  Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. , 1997, The Journal of urology.

[20]  H. Klocker,et al.  Human renal‐cell carcinoma tissue contains dendritic cells , 1996, International journal of cancer.

[21]  P. Dietrich,et al.  In situ demonstration of renal‐cell‐carcinoma‐specific T‐cell clones , 1996, International journal of cancer.

[22]  B L Levine,et al.  Human naive and memory T lymphocytes differ in telomeric length and replicative potential. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[23]  E. Tartour,et al.  Non-cytotoxic CD4 tumour-infiltrating lymphocytes induce responses in patients with metastatic renal cell carcinoma previously treated with interleukin-2. , 1995, European journal of cancer.

[24]  B. Seliger,et al.  Cellular immune response to human renal‐cell carcinomas: Definition of a common antigen recognized by HLA‐A2‐restricted cytotoxic T‐Lymphocyte (CTL) clones , 1994, International journal of cancer.

[25]  F. Sallusto,et al.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.

[26]  R. Figlin,et al.  Interferon-α Primed Tumor-Infiltrating Lymphocytes Combined with Interleukin-2 and Interferon-α as Therapy for Metastatic Renal Cell Carcinoma , 1993 .

[27]  B. Dréno,et al.  High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy. , 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[28]  J. Douillard,et al.  Apoptosis induced by sodium butyrate treatment increases immunogenicity of a rat colon tumor cell line , 2004, Apoptosis.

[29]  L. Sobin,et al.  Union Internationale Contre le Cancer (UICC) and the American Joint TNM Staging of Renal Cell Committee on Cancer (AJCC) Carcinoma , 1997 .

[30]  E. Lopez Hänninen,et al.  Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. , 1996, The Journal of urology.

[31]  M. Hayakawa,et al.  Treatment of advanced renal cell carcinoma using regional arterial administration of lymphokine-activated killer cells in combination with low doses of rIL-2. , 1994, Urologia internationalis.

[32]  E. Klein,et al.  Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line. , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.